Breast neoplasm

This early-stage study tests whether a DNA vaccine that targets a protein called mammaglobin-A (found on many breast cancer cells) is safe for people with ER+, HER2- breast cancer. The vaccine is given alongside standard hormone therapy or chemotherapy before surgery. The study i…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assi…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This study tests whether adding the experimental drug capivasertib to standard hormone therapy and CDK4/6 inhibitors can delay cancer growth in people with advanced HR+/HER2- breast cancer that cannot be removed by surgery or has spread. About 895 adults whose cancer has not resp…

This phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…

This Phase 3 trial is testing whether a new drug called giredestrant, combined with palbociclib, works better than the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive eit…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…

This early-stage trial is testing a new drug called GDC-9545 (giredestrant), alone or combined with other medications, in people with advanced ER-positive breast cancer that has spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 18…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This pilot trial is testing whether a lower-toxicity chemotherapy combination can be a feasible option for adults aged 70 and older with HER2-negative breast cancer. The study aims to see how well older patients tolerate the treatment and whether they can complete the planned cou…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…

This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This phase 3 trial is testing whether the drug trastuzumab deruxtecan (T-DXd), alone or with other chemotherapy drugs, works better than standard treatment before surgery in people with high-risk HER2-positive early breast cancer. About 927 participants will receive one of three …

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests whether a very low-carb (ketogenic) diet, a low-carb diet, or the diabetes drug canagliflozin can prevent high blood sugar and possibly make standard cancer therapy more effective. It involves 15 people with advanced, hormone-receptor-positive breast cancer that …

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This study is testing whether giving radiation therapy tailored to each patient's risk level can reduce arm swelling (lymphedema) while still controlling cancer in women with early-stage breast cancer that has spread to a sentinel lymph node. Participants receive either whole bre…

This Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be rand…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This Phase 3 trial is testing a new daily pill called camizestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 5,500 people with ER+/HER2- early breast cancer who have a moderate-to-high risk of the cancer returning. Participants take the drug f…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This study tracks how well freezing breast tumors (cryoablation) works together with hormone therapy for women aged 70 and older with low-risk, early-stage breast cancer. Researchers will follow 400 participants for up to 5 years to see how often the cancer comes back. The goal i…

This study looks at whether people with HER2-positive metastatic breast cancer who have had their cancer controlled for at least three years can safely stop their anti-HER2 therapy. About 82 participants will either stop or continue treatment to see if the cancer stays away for a…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This trial is testing whether an experimental drug called SHR-A1811 can slow the growth of HER2-low breast cancer that has returned or spread, compared to standard chemotherapy chosen by the doctor. The study enrolls about 551 adults whose tumors have low levels of HER2, a protei…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This study looks at whether high-dose vitamin D and a home exercise program (walking and strength training) can help prevent bone loss in women being treated for breast cancer. About 191 postmenopausal women with early-stage breast cancer will take either vitamin D or a placebo, …

This study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …

This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study …

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This study looks at whether using ultrasound before surgery can help identify women with early-stage HR+/HER2- breast cancer who have only a few affected lymph nodes. If so, they may be able to have a less invasive sentinel lymph node biopsy instead of a more extensive axillary l…

This study tests whether adding vericiguat to standard heart failure care can improve heart function in people with breast cancer who developed heart problems after cancer treatment. Participants will be randomly assigned to receive either vericiguat plus usual care or usual care…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study has two parts. First, it screens people with HR+ HER2-low metastatic breast cancer who are on standard CDK4/6 inhibitor therapy to find those with lingering tumor DNA in their blood—a sign of high relapse risk. Then, those high-risk patients receive the drug trastuzuma…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This phase III trial is testing whether adding the drug everolimus to standard hormone therapy can help prevent breast cancer from coming back in women with ER-positive, HER2-negative breast cancer who are at high risk of relapse. Participants have already completed at least one …

This trial is testing whether combining four drugs—anastrozole, palbociclib, trastuzumab, and pertuzumab—can safely and effectively treat HR-positive, HER2-positive metastatic breast cancer as a first-line therapy. The study involves people who have not received prior systemic tr…

This phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This study tests a new drug called BL-M07D1, alone or combined with other medicines, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if these treatments shrink tumors and how safe they are. About 83 a…

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positiv…

This study tests a new drug called BL-B01D1 against standard chemotherapy in about 383 people with advanced HR+HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth or improve survival. Participants ar…

This trial tests whether radiation therapy alone can control breast cancer that has spread to nearby lymph nodes as well as surgery to remove those nodes. Women with stage II or III breast cancer who still have cancer in their sentinel lymph node after chemotherapy are randomly a…

This phase 3 trial is comparing an experimental drug, BL-M07D1, against the approved therapy T-DM1 in people with advanced HER2-positive breast cancer that has not responded to previous treatments. The study aims to see whether BL-M07D1 can delay cancer progression better than T-…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This trial tests a new breast implant called REGENERA in women aged 40–70 who are having a lumpectomy for early-stage breast cancer. The implant is placed during the same surgery to fill the gap left by the removed tumor. The study aims to see if the implant is safe and whether s…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This phase 3 trial is testing an experimental oral drug called imlunestrant, alone or combined with abemaciclib, against standard hormone therapies for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after prior hormone treatment. The study aims to se…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This trial tests whether placing a small marker clip into a breast tumor without ultrasound guidance (using touch alone) is as accurate, safe, and cost-effective as using ultrasound. The study involves 50 women with palpable breast tumors who will receive neoadjuvant chemotherapy…

This phase 2 trial tests whether adding immune-boosting drugs (avelumab and utomilumab) to standard chemotherapy and targeted therapy can help people with HER2-positive metastatic breast cancer whose disease has worsened after prior treatments. Participants are randomly assigned …

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This study tests the safety of specially prepared T cells that target a protein called mesothelin, found on some breast cancer cells. The cells are collected from the patient's blood, modified in a lab, and then given back along with chemotherapy and another drug. The trial enrol…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This study looks at whether a 16-20 week exercise and coaching program can reduce inflammation and protect blood vessel health in Black and White women undergoing chemotherapy for breast cancer. Researchers will measure fitness, blood vessel function, and quality of life. The goa…

This study tests a combination of two drugs—sacituzumab govitecan and talazoparib—in people with metastatic triple-negative breast cancer that has spread. The goal is to see if the combo can shrink tumors or slow the disease. About 75 adults with advanced cancer are taking part. …

This trial investigates whether breast cancer patients with cancer in 1-2 sentinel lymph nodes can safely avoid additional armpit surgery (axillary clearance). The study compares survival and cancer recurrence in patients who have the extra surgery versus those who do not. The go…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study looks at how well older patients (65 and up) with advanced or metastatic breast cancer tolerate a chemotherapy drug called Abraxane. The goal is to see what side effects occur and whether the drug can control tumor growth. Participants receive Abraxane intravenously, a…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This study looks at whether weight-loss surgery (sleeve gastrectomy) combined with lifestyle changes, or lifestyle changes alone, can help women who have had early-stage breast cancer and are obese. The goal is to see if losing weight might lower the chance of the cancer returnin…

This trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and HER2-targeted drugs can destroy more cancer before surgery in people with HER2-positive breast cancer. Participants receive one of three treatment combinations befo…

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This study tests whether giving olaparib (a PARP inhibitor) alone or combined with durvalumab (an immunotherapy) before surgery can eliminate or shrink tumors in people with BRCA-mutated, HER2-negative early breast cancer. Participants receive one of the two treatments for 4–6 mo…

This clinical trial is testing whether combining two drugs, palbociclib and bicalutamide, is safe and effective for people with a specific type of metastatic breast cancer that is triple-negative and androgen receptor positive. The study involves women whose cancer has spread and…

This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal …

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plu…

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This pilot trial investigates whether hydroxychloroquine (a malaria drug) and everolimus (an immune-suppressing drug), taken alone or together, can help prevent breast cancer from returning in high-risk patients. The study enrolls people who have completed primary treatment for s…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This phase 2 trial investigates whether adding the targeted drug palbociclib to standard endocrine therapy (letrozole or tamoxifen) improves tumor shrinkage before surgery in people with hormone receptor positive, HER2 negative breast cancer. The study includes both invasive lobu…

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This study compares two modern, wire-free methods for locating non-palpable breast lesions before surgery: radioguided occult lesion localization (ROLL) using a radioactive tracer, and magnetic seed localization. The goal is to see which technique more reliably achieves clear sur…

This study looks at giving a single dose of radiation directly to the tumor site during breast-conserving surgery in women aged 60 and older with early-stage, hormone-sensitive breast cancer. The goal is to see if this shorter, targeted approach controls the cancer as well as sta…

This phase 2 trial is testing how well older adults (60+) with advanced HER2+ breast cancer tolerate a combination of two targeted drugs: lapatinib and trastuzumab. The study enrolled 40 participants and focuses on side effects, especially heart-related issues and severe toxiciti…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…

This study tests whether losartan, a drug already used for high blood pressure, can reduce scarring (fibrosis) caused by radiation therapy in breast cancer patients. 43 women who had breast surgery and need radiation will receive either losartan or a placebo. Researchers will mea…

This study is testing whether women over 55 with a specific low-risk type of breast cancer (luminal A) can avoid radiation after lumpectomy. Instead, they take hormone-blocking pills for 5 years. Researchers are tracking 500 women for 10 years to see how many have the cancer come…

This phase 2 trial investigates whether a program of regular walking and a plant-based diet can lower aromatase levels in overweight postmenopausal women with hormone receptor-positive breast cancer who are already taking an aromatase inhibitor. Participants are randomly assigned…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a shorter course of radiation (hypofractionated) to the breast and nearby lymph nodes in 137 women with node-positive breast cancer. The goal is to see if this approach reduces arm swelling (lymphedema) and other side effects while still preventing cancer from co…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-stage trial is testing whether focused ultrasound (sound waves aimed at tumors) combined with a low dose of the chemotherapy drug gemcitabine can boost the immune system's ability to fight early breast cancer. About 32 participants will receive either ultrasound, low-d…

This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The mai…

This phase II study tests whether adding alpelisib (a targeted pill) to standard fulvestrant (a hormone-blocking shot) can delay cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has wors…

This early-phase trial tests whether a DNA vaccine made from a rat HER2 gene can safely stimulate the immune system in people with advanced or high-risk HER2-positive breast cancer. Thirteen participants receive multiple injections of the vaccine at different doses. The main goal…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already t…

This study tests whether giving radiation over just 5 days in a row, instead of the usual longer schedule, is safe and works well for breast cancer patients who have had a mastectomy and breast reconstruction. The goal is to prevent cancer from coming back in the chest or nearby …

This study tests whether closely monitoring arm swelling after breast cancer surgery and treating it early with a compression sleeve can prevent long-term lymphedema. 250 women who had many lymph nodes removed will be randomly assigned to either the monitoring program or usual ca…

This phase 2 trial is testing a higher dose (500 mg) of the hormone therapy fulvestrant (Faslodex) as a first treatment for postmenopausal women with hormone receptor positive metastatic breast cancer. The study aims to see if this higher dose improves clinical benefit rates comp…

This phase 2 trial is testing whether adding the immunotherapy drug atezolizumab to a standard combination of chemotherapy (paclitaxel) and two targeted drugs (trastuzumab and pertuzumab) is safe and effective for people with advanced HER2-positive breast cancer that has spread. …

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This study looks at whether surgically removing the primary breast tumor (along with standard chemotherapy) helps women with oligometastatic breast cancer—cancer that has spread to only a few spots in the body—live longer. About 110 women in Pakistan will either receive surgery p…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA- or PALB2-mutated breast cancer. The goal is to see if this combination boosts the immune system's attack on the tumor and leads to a complete response (no cancer left at surgery). Abo…

This phase 2 trial is testing whether a combination of ribociclib (Kisqali) and letrozole can safely replace chemotherapy for people with high-risk ER+/HER2- breast cancer. About 1100 participants will first receive the drug combo before surgery. If their tumor shows a low risk o…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This study tests whether adding a non-invasive heat therapy called modulated electro-hyperthermia (mEHT) to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive chemo with …

This early-stage trial tests a new drug called YL202 in about 80 people with advanced lung or breast cancer that has not responded to standard treatments. The drug is given by IV every three weeks. The main goal is to check safety and find the right dose, not yet to prove it work…

This study tests a newer targeted therapy, trastuzumab deruxtecan (T-DXd), against an older one, trastuzumab emtansine (T-DM1), in about 1,600 people with high-risk HER2-positive breast cancer who still have cancer after initial treatment. The goal is to see if T-DXd can better p…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab, with or without fulvestrant) for HER2-positive breast cancer. In the first part, it looks at safety in patients whose cancer has spread. In the second part, it compares these drugs to standard c…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study looks at whether a targeted therapy called palbociclib, taken for 2 years alongside standard hormone therapy, can help prevent breast cancer from coming back in older patients with high-risk ER+/HER2- early breast cancer. The goal is to offer an effective alternative t…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team interv…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests if a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with a common type of early breast cancer (HR+/HER2-). About 1,684 women with intermediate-risk disease are taking part. The goal is to see whic…

This study looks at whether women with early breast cancer (tumors smaller than 5 cm) and no signs of cancer in the lymph nodes can safely avoid axillary surgery. About 800 women will be randomly assigned to either have a sentinel lymph node biopsy or no surgery at all. The goal …

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This phase 3 trial compares a standard 3-week radiation course to an experimental 2-week course for women with early-stage breast cancer. About 400 participants who had lumpectomy will receive whole breast radiation plus an extra boost to the tumor site. The study checks if the s…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This study tests a modified radiation schedule for women aged 50 and older with early-stage, low-risk breast cancer. Instead of the standard every-other-day treatment over 10 days, participants receive five daily radiation sessions with a slightly lower dose each day. The goal is…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This phase II trial tests a drug called sacituzumab govitecan in 44 patients with HER2-negative breast cancer that has spread to the brain. The drug is a targeted antibody that delivers chemotherapy directly to cancer cells. The goal is to see if it can shrink brain tumors or slo…

This study tests whether a single, focused radiation treatment works as well as five treatments for people with low-risk stage 0 or I breast cancer after a lumpectomy. About 134 participants will be randomly assigned to receive either one or five doses of radiation to the tumor a…

This phase 3 trial compares giving hormone therapy (aromatase inhibitors) at the same time as chemotherapy versus after chemotherapy in 1000 postmenopausal women with early breast cancer. The goal is to see which timing better prevents the cancer from coming back over 15 years. P…

This phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This study compares two approaches for women with early-stage invasive breast cancer undergoing breast-conserving surgery: no axillary surgery versus sentinel lymph node biopsy. The goal is to see if avoiding axillary surgery leads to the same cancer outcomes while reducing compl…

This phase III trial tests whether a less extensive lymph node surgery (tailored axillary surgery) followed by radiotherapy works as well as the standard full lymph node removal in women with breast cancer that has spread to the lymph nodes. The study involves 1,500 participants …

This study tested different chemotherapy combinations and schedules for women with breast cancer that had spread to lymph nodes. The goal was to see if adding a drug called fluorouracil or giving chemo every 2 weeks (with a support drug to boost immune recovery) worked better tha…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This study looks at a new material called SC Derm, used in breast reconstruction after mastectomy for breast cancer. It compares how well this material works and its safety against other similar products. About 120 women aged 20 to 69 who are having a mastectomy and immediate imp…

This Phase III trial is testing whether women and men with early-stage, low-risk HER2-positive breast cancer can safely skip radiation after breast-conserving surgery if they continue HER2-targeted therapy. About 1,300 participants are randomly assigned to receive either standard…

This trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…

This early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combina…

This study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. While the approach aims to m…

This phase 2 trial tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. First, patients receive a strong drug called trastuzumab deruxtecan (T-DXd) to shrink the cancer. Then, they switch to a maintenance therapy …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took …

This phase 3 study tests whether adding the targeted drug abemaciclib to standard hormone therapy helps prevent breast cancer from returning in people with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to lymph nodes. Over 5,600 pa…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to two standard targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in people with HER2-enriched breast cancer. The study involves 51 participants and measures how many have no or…

This study is testing a shorter, more intense radiation schedule (hypofractionation) for women with breast cancer who have had surgery. The goal is to see if this approach is safe and effective at preventing cancer from coming back while reducing side effects like arm swelling. F…

This study tests whether giving the immunotherapy drug pembrolizumab (Keytruda) along with a small dose of radiation to the tumor before standard treatment (surgery, chemotherapy, or radiation) is safe and helps the immune system fight breast cancer. About 66 people with operable…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study tests whether giving two targeted drugs, T-DM1 and pertuzumab, before surgery can completely eliminate early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the drugs for 18 weeks, then undergo surgery. The main goal …

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This Phase III trial tests whether adding the experimental drug TQB3616 to standard hormone therapy can help prevent breast cancer from returning in women with HR-positive, HER2-negative breast cancer after surgery. About 1,946 women will receive either TQB3616 or a placebo, plus…

This study aimed to test the safety and effectiveness of combining the drug ribociclib with hormone therapy and radiation for women aged 70 and older with a certain type of breast cancer. The goal was to control the disease without surgery. However, the study was withdrawn before…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study tests a different dosing schedule of the chemotherapy drug capecitabine combined with the targeted therapy neratinib in people with advanced HER2-positive breast cancer. The goal is to find the safest dose that still works. About 34 adults with stage IV breast cancer t…

This early-phase study tests an oral drug called LY3484356 in 17 Chinese patients with advanced ER+/HER2- breast cancer. The main goals are to see how the drug moves through the body and to check its safety. Researchers will also look for signs that the drug can shrink tumors or …

This study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…

This early-phase study tests a new immune-boosting drug (DPX-Survivac) combined with hormone therapy, with or without low-dose radiation or chemotherapy, in women with hormone receptor-positive, HER2-negative breast cancer. The main goal is to check safety before standard surgery…

This phase 2 study tests a new drug (TQB3616) combined with hormone therapy for people with a common type of breast cancer (HR-positive, HER2-negative) that has returned or spread and no longer responds to a standard class of drugs called CDK4/6 inhibitors. The trial enrolls 33 a…

This early-phase trial tests a two-step treatment for advanced breast cancer that cannot be cured with surgery or radiation. First, patients receive a drug called talazoparib alone, then both talazoparib and avelumab together. The main goal is to check safety and side effects, wh…

This phase 3 trial tests whether adding the drug palbociclib to standard hormone therapy can help prevent breast cancer from coming back in people with a specific type of breast cancer (HR+/HER2-). About 405 participants who had surgery for a local or regional recurrence will rec…

This small study is testing whether hyperbaric oxygen therapy (HBOT) can help control the growth of breast cancer that has spread to the lungs. Ten women with advanced breast cancer and lung metastases will receive standard cancer treatment plus HBOT sessions. The goal is to see …

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study looks at a way to help women under 40 with breast cancer keep their ability to have children after chemotherapy. Before starting chemo, participants receive hormone injections and tamoxifen to stimulate their ovaries, then eggs or embryos are frozen. The goal is to see…

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…

This study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the …

This study compares an oral version of the chemotherapy drug paclitaxel (Liporaxel) with the standard IV version (Taxol) in 549 people with recurrent or metastatic HER2-negative breast cancer. The goal is to see if the pill works as well or better at controlling the disease and i…

This study tests a new drug called CFI-402257 combined with the standard chemotherapy paclitaxel in people with advanced HER2-negative breast cancer that cannot be cured. The goal is to see if the combination works better than paclitaxel alone at slowing tumor growth. About 37 wo…

This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer retu…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study compares a 1-week radiation schedule to the standard 3.1-week schedule for people with early-stage breast cancer who have had lumpectomy. The goal is to see if the shorter course controls cancer just as well while causing fewer side effects. About 72 adults with ductal…

This study tests whether a highly focused type of radiation called stereotactic body radiation therapy (SBRT) can delay cancer progression in women with metastatic breast cancer who are starting their first treatment. About 154 participants will receive either standard therapy al…

This phase 2 trial is testing whether adding the targeted drug dalpiciclib to standard hormone therapy (letrozole) before surgery can improve outcomes for women with HR+/HER2- early-stage breast cancer. The study enrolls 100 women aged 18-70 whose tumors have a high genetic risk …

This phase 3 trial is testing whether the targeted drug trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy for people with a specific type of advanced breast cancer called HER2-low, hormone receptor positive. The study includes 866 participants whose cancer ha…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This study looks at whether a special type of mammogram called contrast-enhanced mammography (CEM) can more accurately predict breast cancer in women with suspicious calcium spots in the breast. About 59 women with large areas of these spots will get both a standard mammogram and…

This study tests a special type of mammogram called CESM, which uses a dye injected into a vein to make breast tissue and blood vessels clearer. The goal is to see if CESM is better than standard mammograms at finding the cause of nipple discharge and detecting breast cancer. Abo…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial tests whether tomosynthesis (a 3D X-ray technique) combined with synthetic 2D images can reduce the number of advanced and interval breast cancers compared to standard digital mammography. Over 10,000 women scheduled for routine screening will be randomly assigned to o…

This phase 1 trial tests whether a new radioactive imaging agent, 89Zr-ss-pertuzumab, is safe for detecting HER2-positive breast cancer in 60 participants. The agent is designed to bind to HER2 proteins on cancer cells and show up on PET/CT scans. The main goal is to check for si…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study tests a new MRI technique called virtual MR elastography (vMRE) that uses standard scans to measure breast tissue stiffness, which can help tell benign from malignant lesions. Researchers will compare vMRE to the traditional MRE method in 238 women with suspicious brea…

This study is testing whether a simple breath test can tell if a woman has breast cancer. Researchers are collecting breath samples from 1000 women — half with breast cancer and half without — and analyzing them with a mass spectrometer. The goal is to see if the chemical signatu…

This study tests whether checking sentinel lymph nodes during breast cancer surgery (using a rapid freezing method) helps surgeons decide right away if more lymph nodes need to be removed, compared to the usual method of waiting for final results after surgery. About 142 women wi…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study compares breast ultrasound with two types of breast MRI (abbreviated and full protocol) for detecting new breast cancers in women who have dense breasts and a personal history of breast cancer. About 1,756 women will be randomly assigned to one of the screening methods…

This study is testing an artificial intelligence (AI) tool that analyzes digitized images of tumor tissue from 2,200 women with ER-positive, HER2-negative early breast cancer. The AI aims to predict the risk of cancer spreading to distant parts of the body. Researchers will compa…

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple…

This study tests a low-cost, portable ultrasound device (POCUS) combined with artificial intelligence to detect breast cancer in women with suspicious symptoms. The goal is to see if this approach works as well as standard imaging, especially in places where expensive equipment i…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study tests whether a lifestyle program combining aerobic exercise, strength training, and dietary coaching can reduce breast cancer risk in normal-weight postmenopausal women. The goal is to lower body fat and inflammation, which are linked to higher cancer risk even in wom…

This study tests whether a program that includes diet advice, physical activity, stress management, mindfulness, sleep tips, and counseling can help prevent breast cancer in premenopausal women at higher risk. About 60 women will take part to see if the program is practical and w…

This study tests whether sending personalized print materials and a follow-up phone call can encourage women who had childhood cancer to get mammograms. Participants are 360 women aged 25-49 who received chest radiation as children and haven't had a mammogram in two years. The go…

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This study tests whether different amounts of progressive aerobic exercise can reduce risk factors for breast cancer in women who are at high risk. Participants will follow an exercise program, and researchers will measure changes in exercise capacity, body composition, and gene …

This study tests whether a 6-month program combining Bollywood-style dance classes and a fitness tracker can increase physical activity and improve metabolic health in South Asian Indian immigrant women aged 40-65 who are not very active. The goal is to see if this culturally tai…

This study tests whether a mobile application can help breast cancer survivors prevent lymphedema, a common and often permanent swelling of the arm after surgery. Participants who had breast cancer surgery at least one month ago will be randomly assigned to use the app or receive…

This study tests a web-based nurse navigator program designed to encourage breast cancer screening (mammograms, breast self-exams, and clinical exams) in women at high risk for breast cancer. 104 women aged 30-70 who haven't had a mammogram in the last year are participating. The…

This phase 3 trial tests whether taking metformin for 12 months can reduce abnormal cells in the breast tissue of women at high risk for breast cancer. Participants have conditions like atypical hyperplasia or a strong family history. Researchers compare metformin to a placebo to…

This study tests whether a special surgical technique called Axillary Reverse Mapping (ARM) can prevent lymphedema (arm swelling) in breast cancer patients who need lymph node removal. The ARM technique aims to preserve the arm's lymph drainage during surgery. 100 patients will b…

This study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is t…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study compares two creams, Aquaphor and Miaderm, to see which one better treats skin irritation caused by radiation therapy in breast cancer patients. About 208 women with early-stage breast cancer will use one of the creams during their radiation treatment. The goal is to f…

This study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…

This study tested a 24-week weight loss program delivered via video calls for 22 breast cancer survivors who were overweight or obese. The goal was to see if the program was practical and well-liked, and whether it improved quality of life, physical activity, and mood. Participan…

This study looks at whether a regular exercise program is practical for women aged 65 and older who are receiving chemotherapy for early-stage breast cancer. Participants will be asked to walk and do arm exercises several times a week. The goal is to see if exercise can reduce th…

This trial asks whether starting sexual health support early and systematically helps women with localized breast cancer feel better about their sexual well-being compared to waiting until they ask for help. Women aged 18 and older who are beginning treatment with surgery will re…

This study tests whether an AI system that analyzes social media posts can improve quality of life for breast cancer patients. 440 women will either use the AI system plus usual care or just usual care for 6 months. The goal is to see if personalized emotional support reduces anx…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This study looks at whether a mobile health program that combines physical activity tracking with mindfulness lessons can help breast cancer survivors become more active and feel better. About 304 women who finished cancer treatment within the past 5 years will take part in a 24-…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This study looks at whether women aged 65 and older with early-stage, estrogen-positive breast cancer can safely have a lumpectomy without also removing and testing nearby lymph nodes (sentinel node biopsy). The goal is to see if skipping this extra step leads to cancer coming ba…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This trial tests whether acupuncture can prevent taxane-induced peripheral neuropathy (TIPN) — nerve damage causing pain and tingling in arms and legs — from worsening in breast cancer patients receiving weekly taxane chemotherapy. Participants with early-stage breast cancer who …

This trial tests whether adding bupivacaine, a numbing medicine, directly into the surgical wound after a mastectomy can improve pain control and reduce the need for opioid painkillers. Participants receive either bupivacaine or a placebo through a drain placed in the wound, alon…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study tests a personalized self-management program to help cancer survivors on immune checkpoint inhibitors better handle side effects and reduce anxiety or depression. About 400 adults with breast, colon, lung, skin, or rectal cancer who recently started immunotherapy will …

This study tests an 8-week telehealth occupational therapy program designed to help breast cancer survivors increase physical activity after breast-conserving surgery or mastectomy. The program is delivered via Zoom and focuses on each survivor's preferred activities. Researchers…

This trial tests whether a three-week physiotherapy program, starting one week after breast reduction surgery, can reduce pain, improve posture, and boost quality of life. Forty women aged 18 to 50 who have had their first breast reduction will be split into two groups: one recei…

This study tests whether a high-CBD plant extract can reduce joint stiffness and pain in women with breast cancer who take aromatase inhibitors. These drugs lower estrogen to prevent cancer return but often cause painful joints, leading some women to stop treatment. The trial wil…

This study tests whether a 12-week home exercise program, guided by telehealth check-ins, can reduce fatigue in cancer survivors living in rural Colorado. Participants follow a personalized plan of aerobic and resistance exercises, with intensity adjusted based on their progress.…

This trial looks at whether supervised aerobic exercise is more beneficial when done during chemotherapy or after it ends for women with early-stage breast cancer. Participants are randomly assigned to exercise during treatment, after treatment, or to receive only educational mat…

This study tests whether Moutan Cortex, a Chinese herb containing paeonol, can relieve nerve pain and numbness caused by chemotherapy in breast cancer patients. Participants take the herb or a placebo daily for four weeks. Researchers measure pain levels and nerve function to see…

This study tests whether an online pain coping skills training program can reduce joint, bone, and muscle pain in breast cancer survivors who take aromatase inhibitors (AIs). Participants are women who have completed primary cancer treatment and experience AI-related joint pain. …

This study tests whether sexual counseling delivered via WhatsApp can help breast cancer survivors who have sexual problems after treatment. About 86 women who have had mastectomy and finished chemo/radiotherapy will receive counseling using the EX-PLISSIT model. The goal is to s…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study tests whether structured hypnotherapy sessions can improve quality of life for women with breast cancer undergoing chemotherapy. Participants in the intervention group receive 10 hypnotherapy sessions alongside standard care, while the control group receives standard c…

This study compares two types of nerve blocks (retrolaminar block vs. serratus anterior plane block) to see which provides better pain relief after radical mastectomy. About 90 women aged 25-65 undergoing breast cancer surgery will receive one of the blocks before general anesthe…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests whether a 6-week online yoga program can improve quality of life, reduce joint pain, and lessen night sweats and hot flashes in women with breast cancer who are taking endocrine therapy. About 64 women will take part, with half doing yoga four days a week and the…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tested if a scalp cooling cap set to a colder temperature than usual can safely prevent hair loss in breast cancer patients receiving chemotherapy. 34 adults with stage I-III breast cancer took part. The goal was to see if the lower temperature is safe and tolerable.

This study tests whether a cream made with caffeine can help prevent skin hardening and other complications in breast cancer patients who need radiation after mastectomy with tissue expander reconstruction. About 60 participants will use either the caffeine cream or a placebo cre…

This study looks at whether a 12-week dance program can reduce pain, fatigue, and improve quality of life in women being treated for breast cancer. Twenty-eight women will either take dance classes twice a week or continue their normal routine. Researchers will measure changes in…

This study is testing whether a 9-month, individually tailored exercise program can reduce physical fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants work with a trained instructor to follow a personalized exercise plan. The main goal is …

This study tests whether a 20-week program of exercise alone or exercise combined with cognitive training can improve thinking and memory in breast cancer survivors. 108 women who have finished primary treatment will be assigned to one of three groups: dual-task training, exercis…

This study tests whether a type of pain education that teaches the brain's role in pain, combined with motivational interviewing, can reduce chronic pain in breast cancer survivors. 156 women who have finished primary treatment and still have pain will be randomly assigned to thi…

This study tests whether a therapy program that combines in-person sessions with a smartphone app can help cancer patients feel more flexible in dealing with difficult thoughts and emotions. About 120 adults with breast, lung, or colorectal cancer will be randomly assigned to one…

This pilot study tests whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS), combined with cognitive training, is feasible and tolerable for breast cancer survivors who have memory or thinking problems after chemotherapy. The st…

This study tests an online self-help program called Together After Cancer for Latina breast cancer survivors and their intimate partners. The program includes brief coach calls and aims to improve the survivor's quality of life and the couple's relationship satisfaction. About 48…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study explores whether music therapy can reduce anxiety, fatigue, and other symptoms in women with breast cancer who are receiving chemotherapy. Twenty-four participants will take part in weekly group music sessions and use personalized playlists at home, alternating periods…

This study looks at whether a special cooling cap, called the Amma system, can help women with early-stage breast cancer keep more of their hair during chemotherapy. Fifteen women will use the cap during each chemo session and answer questions about how satisfied they are. The go…

This study tests a portable scalp cooling system called Amma to see if it can prevent hair loss in women receiving chemotherapy for early-stage breast cancer. Forty women with stage I-III breast cancer will use the cooling cap during their chemo sessions. The goal is to see if mo…

This study tests whether acupuncture can improve thinking problems (like memory and focus) in breast cancer survivors. About 270 women who have finished cancer treatment will receive either real acupuncture, sham acupuncture, or standard care. Researchers will track their cogniti…

This study looks at whether a shorter, more intense course of radiation (accelerated radiation therapy) is safe and tolerable for women with breast cancer who have already had chemotherapy and surgery. About 88 participants will receive the accelerated radiation to the breast and…

This study tests whether regular symptom check-ins via text or email, plus educational materials, can help young women with early-stage breast cancer stay on their hormone therapy. Many women stop treatment early due to side effects. The trial involves 565 women and compares symp…

This study tests whether adding a photo guide to standard counseling helps reduce anxiety and depression in women with early-stage breast cancer who are about to start radiation therapy. About 62 participants will either receive standard verbal counseling alone or with a pictoria…

This study tests whether a smartphone app that sends text reminders can help breast cancer patients take their medication (palbociclib) on time. 45 participants will either use a paper diary or receive text reminders over three treatment cycles. The goal is to see if the app is e…

This study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study follows women with early-stage breast cancer who are about to receive paclitaxel chemotherapy, a treatment that often causes nerve damage. Researchers will use smartwatches and a mobile app to track physical activity, sleep, and stress, alongside clinical exams and ski…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study tested whether radiologists can safely skip looking at detailed 3D breast scans when a quick 2D image or an AI score suggests the case is normal. Sixteen radiologists briefly viewed each case and rated how likely it was normal, then saw the AI's opinion. The goal is to…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study looks at whether a new scoring system, called the DIEP-MDS, can help predict the risk of blood flow problems and flap failure after DIEP flap breast reconstruction. The score is based on CT scans of the abdomen, measuring features of the blood vessels used in the surge…

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study follows breast cancer patients who have had curative surgery and are receiving hypofractionated radiation therapy—shorter treatment courses lasting one to three weeks. Researchers will track changes in breast skin, fibrosis, cosmetic appearance, and patient-reported ou…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study is investigating whether genetic changes in tumor tissue and blood can predict how well people with hormone receptor-positive metastatic breast cancer respond to a combination of endocrine therapy and palbociclib. Researchers will collect tumor samples and blood from p…

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This study is looking at why some people develop persistent pain after breast cancer surgery while others do not. Researchers will follow 220 adults undergoing breast cancer surgery, using questionnaires and a pain sensitivity test to identify risk factors. The goal is to find re…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study aims to create a large collection of blood and tissue samples from people with breast cancer, as well as those at high risk. The samples will be stored and used for future research to better understand, diagnose, and treat breast cancer. Participants will also be asked…

This study aims to learn more about how inherited gene mutations, particularly in the BRCA1 and BRCA2 genes, affect the risk of developing breast and ovarian cancer. Researchers will follow participants with a family history of these cancers, tracking their medical history and fa…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks back at medical records of 150 women with breast cancer to compare two minimally invasive ways of checking whether cancer has spread to lymph nodes under the arm: robotic-assisted and endoscopic-assisted sentinel lymph node biopsy. The goal is to see which method…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study looks at whether two different health programs are practical and acceptable for women who have finished treatment for early-stage breast cancer. One program combines nutrition advice, lifestyle changes, yoga, and therapeutic touch (Ayurveda). The other is a self-guided…

This study is investigating whether testing for a panel of 24 genes, in addition to the well-known BRCA1 and BRCA2 genes, can better estimate the risk of breast and ovarian cancer. Researchers will analyze genetic samples from people with a family history of these cancers, as wel…

This study uses a special PET scan to measure brain inflammation in women with stage II–III breast cancer before and after chemotherapy. The goal is to see whether higher levels of inflammation are linked to memory and thinking problems, often called 'chemo brain.' Twenty women w…

This study combines MRI scans with detailed genetic and molecular analysis (multiomics) to improve how luminal breast cancer is classified and treated. Researchers aim to develop models that predict treatment resistance, recurrence, and spread, helping doctors choose the most eff…

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and wha…

This study explores whether genetic testing from a simple saliva sample can improve risk assessment for breast cancer in women who need a breast biopsy. Researchers will analyze DNA from saliva to calculate a polygenic risk score and compare it with biopsy results and medical rec…

This study explores whether a Nectin-4 PET scan can predict how well a Nectin-4-targeted therapy works in people with advanced breast cancer. Forty participants will receive both a standard PET scan and a Nectin-4 PET scan before starting treatment, and some will have a repeat sc…

This study tests whether teaching breast self-examination using pictures, models, and hands-on demonstrations can increase breast cancer awareness and health motivation in illiterate women aged 15-49 living in rural Turkey. Participants receive face-to-face visual education and a…

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…

This study looks at how chronic noncommunicable diseases like inflammatory bowel disease and breast cancer impact a person's ability to work. Researchers will follow 200 working-age adults for 12 months, collecting data on health, work performance, and well-being. The goal is to …

This study compares two minimally invasive techniques for removing lymph nodes under the arm in people with breast cancer that has spread to those nodes. The goal is to see which method better protects nearby nerves, reduces side effects like numbness or pain, and improves recove…

This study looks back at medical records of 1,950 breast cancer patients to build a tool that predicts whether lymph nodes are cancer-free after chemotherapy. The goal is to identify patients who could safely have a less invasive sentinel node biopsy instead of full lymph node re…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This pilot study is testing whether it's possible to run a larger study that focuses on heart disease in women. Researchers will gather information from 176 women aged 25-55 in Ontario who have had certain female-specific health issues like pre-eclampsia, gestational diabetes, or…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how b…

This study tests five different reminder strategies to encourage women in Singapore who are overdue for mammograms to get screened. About 12,750 women aged 50-69 who have not had a mammogram in over two years will receive reminders by mail, with some getting a pre-scheduled appoi…

This study asks 12 clinicians in Florida who care for women with breast cancer about gaps in emotional and mental health support. They will join virtual focus groups and fill out a short survey. The goal is to use their insights to build an AI-powered digital platform called Mamm…

This study looks at how to best collect information about social and behavioral needs (like housing, food, or transportation) from women newly diagnosed with breast cancer. Researchers will compare different screening tools and methods (like chatbots or phone calls) to see which …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at whether regular blood tests can detect changes in stage IV breast cancer during treatment. Researchers will collect blood samples from 150 adults with metastatic breast cancer and analyze them for tumor DNA. The goal is to see if these tests can spot when the …

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study analyzed stored tumor samples and medical records from nearly 1,900 Greek women who had surgery for early breast cancer. Researchers looked at genetic changes and protein markers in the tumors to see how they relate to breast cancer subtypes and long-term survival. The…

This study looks at how age changes the way the body handles a breast cancer drug called nab-paclitaxel. Researchers are studying 40 people with metastatic breast cancer to see if older patients process the drug differently. The goal is to make chemotherapy safer and more effecti…

This study looks at attention and memory in breast cancer survivors compared to healthy women of the same age. Researchers use EEG to measure brain activity during memory tasks. The goal is to understand why some survivors have trouble focusing or remembering. Results may help de…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study tests whether an AI system can create safe and effective exercise plans for women recovering from breast cancer surgery. Researchers will compare the AI's plans to those made by doctors. The goal is to make rehabilitation more personalized and accessible.

This study looks at why some women with breast cancer in one breast later develop cancer in the other breast. Researchers are comparing women with cancer in both breasts to those with cancer in only one breast. They are studying how genes, past radiation treatment, and lifestyle …

This study examines whether medications given during mastectomy to keep blood pressure stable might affect the risk of breast cancer coming back. Researchers will review the records of 250 patients who had mastectomy over five years. They will look at which drugs were used and tr…

This study looks at how breast cancer treatment impacts women's jobs, finances, and daily life, especially comparing women from different ethnic groups. About 935 breast cancer survivors who were working before or during treatment will share their experiences. The goal is to unde…

This study tests a web-based tool called gp-multitool.de that helps general practitioners follow guidelines for older patients with multiple chronic conditions. About 659 patients from GP practices in Germany are taking part. The tool lets patients fill out questionnaires online …

This study involves 15 postmenopausal women with metastatic ER+ breast cancer. Researchers are testing a special PET scan that uses a radioactive tracer to see estrogen receptors on tumors. The goal is to find the best way to measure these receptors, which could help doctors know…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study looks at whether it is safe to have an MRI scan when you have breast tissue expanders in place. About 68 people with these expanders will be scanned, and researchers will check for any burning, heating, or pain. The goal is to see if MRI can be done safely in this grou…

The FATLAS study is looking at how body fat (adiposity) influences breast cancer at both the whole-body and cellular levels. Researchers will enroll 150 breast cancer patients with different body types (lean, overweight, obese) and collect blood, tumor tissue, and body measuremen…

This study looks back at nearly 3,000 women with early-stage invasive breast cancer to see if routine blood test results, along with tumor details, can help predict how the disease will progress. Researchers will track cancer recurrence and survival over time. The goal is to find…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study creates a long-term repository of blood, tissue, and health information from 810 people with breast cancer, benign breast disease, or no breast issues. The goal is to provide researchers with resources to better understand breast cancer. No treatment or experimental th…

This study looks at whether the small white moons at the base of fingernails (lunula) can predict how well breast cancer patients respond to chemotherapy before surgery. Researchers will track 188 patients to see if lunula status is linked to tumor disappearance and side effects.…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study looks at whether people with HER2-positive breast cancer can safely have fewer heart check-ups while on a specific type of treatment (trastuzumab without anthracyclines). About 190 participants will be followed to see if less monitoring leads to serious heart problems.…

This study is a registry that tracks side effects and outcomes in people who have undergone cryoablation (freezing) for early stage breast cancer. It is not testing a new treatment but rather collecting real-world data on symptoms, complications, and follow-up results. Only 2 par…

This study collects medical information and tumor samples from 200 men with breast cancer to better understand the disease. Researchers will analyze patient characteristics, treatments, and outcomes over time. The goal is to learn more about male breast cancer, which is rare and …

This study is testing a new way to take MRI images of the breast using a very low magnetic field. The goal is to see if this method can produce clearer pictures of breast cancer. About 40 women with benign or malignant breast tumors will be scanned, and the results will be compar…

This study tests a new program to help breast cancer patients return to work after treatment. It includes 16 working-age women who have work difficulties. The program offers meetings and support from a team of specialists. The goal is to see if this approach is practical and help…

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study tests a program to improve follow-up care for breast cancer survivors in primary care clinics. The program includes training, expert advice, and feedback for clinic staff. Researchers will see if it helps clinics provide more complete care for managing symptoms and lon…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This study looks at 80 women having breast cancer surgery to see if using a mix of two numbing medicines (levobupivacaine and lidocaine) for a nerve block causes more changes in blood pressure and heart rate than using just one (levobupivacaine alone). The goal is to find which a…

This study looks at whether a physical exercise program can prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. About 70 participants will be randomly assigned to exercise or usual care. Researchers will use heart scans and blood …

This study looks at whether artificial intelligence (AI) can help radiologists find breast cancer earlier when reading mammograms. Researchers will review past mammograms from 785 women, some with breast cancer and some without, to compare how well doctors detect cancer with and …

This study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study looks at whether combining breast MRI with blood and tissue samples can help find early signs of breast cancer in high-risk women. About 344 women will undergo standard screening MRI and donate leftover tissue and blood. The goal is to better understand how normal brea…

This observational study looks at how diet, activity, and lifestyle factors relate to muscle strength and heart health in 14 postmenopausal breast cancer patients who received anthracycline chemotherapy. Researchers will measure changes in heart function, muscle energy, and blood…

This study planned to give high doses of vitamin D to women with breast cancer before their surgery. Researchers wanted to see if the vitamin would change certain markers in the cancer cells. However, the study was withdrawn before any participants were enrolled, so no results ar…

This study looks at whether using loco-regional anesthesia (numbing a specific area) during breast cancer surgery can help prevent chronic pain that often lasts months or years after the operation. About 30% of women experience this long-term pain. Researchers will follow 1,500 p…

This study follows over 1,400 patients in Germany and Austria with HR+/HER2- advanced breast cancer who are receiving standard first-line treatment with palbociclib plus hormone therapy. Researchers are collecting real-world data on how long the cancer stays controlled and overal…

This study follows over 1,100 women with early-stage, hormone-sensitive breast cancer who took the EndoPredict® gene test. Researchers want to see if those classified as 'low risk' can safely receive only hormone therapy without chemotherapy. The goal is to confirm that 10-year s…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study tests whether peer navigators—trained breast cancer survivors—can help African-American women recently finished with breast cancer treatment better understand and stick to their follow-up care plans. About 145 women will either receive standard educational materials or…

This study follows 1,500 women with ductal carcinoma in situ (DCIS), a very early form of breast cancer, who have had breast-conserving surgery. Researchers want to see if a genetic test called DCISionRT helps doctors decide whether to add radiation or hormone therapy after surge…

This study tests whether trained nurses can perform breast exams and guide women through the healthcare system to reduce delays in diagnosing and treating breast cancer. Researchers will enroll 8,000 women in Ethiopia, South Africa, Nigeria, and Tanzania. The goal is to see if th…

This study looks at how breast cancer and its treatments impact the quality of life for patients in Martinique. Researchers will survey 133 adults with invasive breast cancer to understand their physical and emotional well-being, as well as how long treatment takes. The goal is t…

This study involves 2,200 women aged 50–67 to see if personalized mammography screening, based on genetic and lifestyle risk factors, is safe and acceptable. Half the women receive standard biennial mammograms, while the other half get a risk assessment and a tailored screening s…

This study aims to find out how common persistent pain is after mastectomy and breast reconstruction, and whether a nerve surgery called RPNI can help reduce that pain. Researchers will follow 274 women who had mastectomy and reconstruction at Memorial Sloan Kettering. The study …

This study looks at blood samples from 25 cancer patients receiving radiation therapy. Researchers want to find specific genes that show how each person's body responds to radiation. The goal is to better understand individual reactions and possibly personalize radiation treatmen…

This study reviews medical records of 75 women who had a preventive nipple-sparing mastectomy (removing breast tissue while keeping the nipple). The goal is to see how often complications occur within 42 days after surgery. Researchers also check if the surgery successfully remov…

This study follows 238 breast cancer patients to see how chemotherapy impacts their physical function, overall health, and quality of life. Researchers compare older adults (65+) with younger patients to understand recovery patterns and identify who is at higher risk for serious …

This study follows 132 young breast cancer patients who had chemotherapy, with or without a fertility preservation procedure (controlled ovarian hyperstimulation). Researchers track how many become pregnant and give birth over the long term. The goal is to understand how cancer t…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study follows 61 women with lymph-node positive breast cancer to see how two types of radiation therapy affect shoulder and arm function one year after treatment. Participants receive either intensity-modulated radiation therapy (IMRT) or 3D conformal radiation therapy (3DCR…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study aimed to compare a less invasive procedure called vacuum-assisted excision (VAPE) to standard surgery for removing non-cancerous but high-risk breast lesions. The goal was to see if VAPE worked as well, was safer, and left better cosmetic results. However, the study wa…